Clinical updates of B‑cell maturation antigen‑targeted therapy in multiple myeloma (MM) and relapsed/refractory MM (Review)
- Authors:
- Rui Xing
- Meidan Wang
- Liqun Wang
- Mingyue Pan
- Yixi Wang
- Hongwei Zhou
-
Affiliations: Department of Hematology, Dongyang Hospital Affiliated to Wenzhou Medical University, Dongyang People's Hospital, Dongyang, Zhejiang 322100, P.R. China, Faculty of Biology, University of Freiburg, D‑79104 Freiburg, Germany, Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150040, P.R. China, Faculty of Law, University of Freiburg, D‑79098 Freiburg, Germany, Department of Rehabilitation Medicine, Chongqing University Jiangjin Hospital, Chongqing University, Chongqing 402260, P.R. China, Department of Gastrointestinal Surgery, Affiliated Nanhua Hospital, University of South China, Hengyang, Hunan 421002, P.R. China - Published online on: December 6, 2024 https://doi.org/10.3892/ijmm.2024.5468
- Article Number: 27
-
Copyright: © Xing et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Siegel RL, Giaquinto AN and Jemal A: Cancer statistics, 2024. CA Cancer J Clin. 74:12–49. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, Lipp S, Merino J, Prosper F, Emde M, et al: Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody em801 for multiple myeloma treatment. Cancer Cell. 31:396–410. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bazarbachi AH, Al Hamed R, Malard F, Bazarbachi A, Harousseau JL and Mohty M: Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: An update. Blood Cancer J. 12:472022. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Luo R, Onyshchenko K, Rao X, Wang M, Menz B, Gaedicke S, Grosu AL, Firat E and Niedermann G: Adding liposomal doxorubicin enhances the abscopal effect induced by radiation/αPD1 therapy depending on tumor cell mitochondrial DNA and cGAS/STING. J Immunother Cancer. 11:e0062352023. View Article : Google Scholar | |
|
Rahmy S, Cheng X, Wang M, Feng H, Qiu W, Zhao R and Lu X: Organ-specific regulation of CHD1 by acute PTEN and p53 loss in mice. Biochem Biophys Res Commun. 525:614–619. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang M, Rao X, Gaedicke S, Wang L, Menz B, Multhoff G and Niedermann G: Adding a PPARα agonist enhances t cell-mediated effects of RT in combination with anti-PD-1. Int J Radiat Oncol Biol Phys. 120(Suppl 1): e409–e410. 2024. View Article : Google Scholar | |
|
Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, Brudno JN, Stetler-Stevenson M, Feldman SA, Hansen BG, et al: T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 128:1688–1700. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hu M, Wang L, Su D, Yuan Q, Xiao C, Guo L, Wang M, Kang C, Zhang J and Zhou T: Evaluation of mycotoxins, mycobiota and toxigenic fungi in the traditional medicine Radix Dipsaci. Front Microbiol. 15:14546832024. View Article : Google Scholar : PubMed/NCBI | |
|
Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, Yellin O, Nichols CM, Dreyer MP, Ahles CP, et al: Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 158:727–738. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
X R, W M, W G, Z L, W X, C W and W C: Chemotherapy-induced toxic epidermal necrolysis in a patient with multiple myeloma, a case report and literature review. Front Oncol. 13:12274482023. View Article : Google Scholar : PubMed/NCBI | |
|
Salem DA, Maric I, Yuan CM, Liewehr DJ, Venzon DJ, Kochenderfer J and Stetler-Stevenson M: Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma. Leuk Res. 71:106–111. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Fabi A, Bhargava R, Fatigoni S, Guglielmo M, Horneber M, Roila F, Weis J, Jordan K and Ripamonti CI; ESMO Guidelines Committee: Electronic address clinicalguidelines@esmo.org: Cancer-related fatigue: ESMO clinical practice guidelines for diagnosis and treatment. Ann Oncol. 31:713–723. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Friedman KM, Garrett TE, Evans JW, Horton HM, Latimer HJ, Seidel SL, Horvath CJ and Morgan RA: Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells. Hum Gene Ther. 29:585–601. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kleber M, Ntanasis-Stathopoulos I and Terpos E: BCMA in multiple myeloma-A promising key to therapy. J Clin Med. 10:40882021. View Article : Google Scholar : PubMed/NCBI | |
|
Abramson HN: B-cell maturation antigen (BCMA) as a target for new drug development in relapsed and/or refractory multiple myeloma. Int J Mol Sci. 21:51922020. View Article : Google Scholar : PubMed/NCBI | |
|
Yu B, Jiang T and Liu D: BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 13:1252020. View Article : Google Scholar : PubMed/NCBI | |
|
Tai YT, Acharya C, An G, Moschetta M, Zhong MY, Feng X, Cea M, Cagnetta A, Wen K, van Eenennaam H, et al: APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 127:3225–3236. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Coquery CM and Erickson LD: Regulatory roles of the tumor necrosis factor receptor BCMA. Crit Rev Immunol. 32:287–305. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, Gross JA, Greipp PR and Jelinek DF: Expression of BCMA, TACI, and BAFF-R in multiple myeloma: A mechanism for growth and survival. Blood. 103:689–694. 2004. View Article : Google Scholar | |
|
Shah N, Chari A, Scott E, Mezzi K and Usmani SZ: B-cell maturation antigen (BCMA) in multiple myeloma: Rationale for targeting and current therapeutic approaches. Leukemia. 34:985–1005. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Oaknin A, Fariñas-Madrid L, García-Duran C, Martin LP, O'Malley DM, Schilder RJ, Uyar D, Moroney JW, Diaz JP, Spira AI, et al: Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort. J Clin Oncol. 41(Suppl 16): S55082023. View Article : Google Scholar | |
|
Rao X, Onyshchenko K, Wang L, Wang M and Niedermann G: Comparison of two triple therapy regimens for enhancing the abscopal effect in mice. Int J Radiat Oncol Biol Phys. 117:e2562023. View Article : Google Scholar | |
|
Dhakal B, Yong K, Harrison SJ, Mateos MV, Moreau P, van de Donk NWCJ, Sidana S, Popat R, Lendvai N, Lonardi C, et al: First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma. J Clin Oncol. 41:LBA1062023. View Article : Google Scholar | |
|
Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F and Hari PN: Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: A systematic review and meta-analysis. JAMA Oncol. 4:343–350. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, et al: Revised international staging system is predictive and prognostic for early relapse (<24 months) after autologous transplantation for newly diagnosed multiple myeloma. Biol Blood Marrow Transplant. 25:683–688. 2019. View Article : Google Scholar | |
|
Lin J, Zhang G, Lou B, Sun Y, Jia X, Wang M, Zhou J and Xia Z: Identification of copper metabolism-related markers in Parkinson's disease. Ann Med. 56:24250642024. View Article : Google Scholar : PubMed/NCBI | |
|
Strimbu K and Tavel JA: What are biomarkers? Curr Opin HIV AIDS. 5:463–466. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Califf RM: Biomarker definitions and their applications. Exp Biol Med (Maywood). 243:213–221. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Oliva S, Gambella M, Gilestro M, Muccio VE, Gay F, Drandi D, Ferrero S, Passera R, Pautasso C, Bernardini A, et al: Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: A prospective analysis. Oncotarget. 8:5924–5935. 2017. View Article : Google Scholar : | |
|
Jeong TD, Park CJ, Shim H, Jang S, Chi HS, Yoon DH, Kim DY, Lee JH, Lee JH, Suh C and Lee KH: Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells. Korean J Hematol. 47:260–266. 2012. View Article : Google Scholar | |
|
Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Owens RB and Wilson CS: Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: Shed syndecan-1 accumulates in fibrotic regions. Mod Pathol. 14:1052–1058. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Van De Donk NWCJ, Richardson PG and Malavasi F: CD38 antibodies in multiple myeloma: Back to the future. Blood. 131:13–29. 2018. View Article : Google Scholar | |
|
Sanchez E, Gillespie A, Tang G, Ferros M, Harutyunyan NM, Vardanyan S, Gottlieb J, Li M, Wang CS, Chen H and Berenson JR: Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma. Clin Cancer Res. 22:3383–3397. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Flores-Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, Sanoja L, Puig N, Lecrevisse Q, Vidriales MB, et al: Immunophenotype of normal vs myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 90:61–72. 2016. View Article : Google Scholar | |
|
Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, et al: Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 380:1726–1737. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen H, Li M, Xu N, Ng N, Sanchez E, Soof CM, Patil S, Udd K, Bujarski S, Cao J, et al: Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells. Leuk Res. 81:62–66. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, et al: B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 129:2210–2221. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Lee L, Bounds D, Paterson J, Herledan G, Sully K, Seestaller-Wehr LM, Fieles WE, Tunstead J, McCahon L, Germaschewski FM, et al: Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br J Haematol. 174:911–922. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Visram A, Soof C, Rajkumar SV, Kumar SK, Bujarski S, Spektor TM, Kyle RA, Berenson JR and Dispenzieri A: Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood Cancer J. 11:1202021. View Article : Google Scholar : PubMed/NCBI | |
|
Bujarski S, Soof C, Li M, Wang CS, Sanchez E, Emamy-Sadr M, Swift R, Rahbari K, Patil S, Spektor TM, et al: Baseline and early changes in serum B-cell maturation antigen levels predict progression free survival and response status for multiple myeloma patients in a phase 1 trial evaluating ruxolitinib, lenalidomide and methylprednisolone. Blood. 132(Suppl 1): 18942018. View Article : Google Scholar | |
|
Ghermezi M, Li M, Vardanyan S, Harutyunyan NM, Gottlieb J, Berenson A, Spektor TM, Andreu-Vieyra C, Petraki S, Sanchez E, et al: Serum B-cell maturation antigen: A novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 102:785–795. 2017. View Article : Google Scholar : | |
|
Mailankody S, Htut M, Lee KP, Bensinger W, Devries T, Piasecki J, Ziyad S, Blake M, Byon J and Jakubowiak A: JCARH125, anti-BCMA CAR T-cell Therapy for relapsed/refractory multiple myeloma: Initial proof of concept results from a phase 1/2 multicenter study (EVOLVE). Blood. 132(Suppl 1): 9572018. View Article : Google Scholar | |
|
Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, et al: Revised international staging system for multiple myeloma: A report from international myeloma working group. J Clin Oncol. 33:2863–2869. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Dimopoulos MA, Kastritis E, Michalis E, Tsatalas C, Michael M, Pouli A, Kartasis Z, Delimpasi S, Gika D, Zomas A, et al: The international scoring system (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function. Ann Oncol. 23:722–729. 2012. View Article : Google Scholar | |
|
Landgren O and Rajkumar SV: New developments in diagnosis, prognosis, and assessment of response in multiple myeloma. Clin Cancer Res. 22:5428–5433. 2016. View Article : Google Scholar | |
|
Yuregir OO, Sahin FI, Yilmaz Z, Kizilkilic E, Karakus S and Ozdogu H: Fluorescent in situ hybridization studies in multiple myeloma. Hematology. 14:90–94. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Huber D, Voith Von Voithenberg L and Kaigala GV: Fluorescence in situ hybridization (FISH): History, limitations and what to expect from micro-scale FISH? Micro Nano Eng. 1:15–24. 2018. View Article : Google Scholar | |
|
Laurent SA, Hoffmann FS, Kuhn PH, Cheng Q, Chu Y, Schmidt-Supprian M, Hauck SM, Schuh E, Krumbholz M, Rübsamen H, et al: γ-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. 6:73332015. View Article : Google Scholar | |
|
Coquery CM, Loo WM, Wade NS, Bederman AG, Tung KS, Lewis JE, Hess H and Erickson LD: BAFF regulates follicular helper t cells and affects their accumulation and interferon-γ production in autoimmunity. Arthritis Rheumatol. 67:773–784. 2015. View Article : Google Scholar : | |
|
Oliva S, Bruinink DHO, Rihova L, D'Agostino M, Pantani L, Capra A, van der Holt B, Troia R, Petrucci MT, Villanova T, et al: Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. Blood Cancer J. 11:1062021. View Article : Google Scholar : PubMed/NCBI | |
|
Sanchez E, Tanenbaum EJ, Patil S, Li M, Soof CM, Vidisheva A, Waterman GN, Hekmati T, Tang G, Wang CS, et al: The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker. Expert Rev Mol Diagn. 18:319–329. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Montes De Oca R, Alavi AS, Vitali N, Bhattacharya S, Blackwell C, Patel K, Seestaller-Wehr L, Kaczynski H, Shi H, Dobrzynski E, et al: Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo. Mol Cancer Ther. 20:1941–1955. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Hoos A, Gupta I, Bragulat V, et al: Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 9:372019. View Article : Google Scholar : PubMed/NCBI | |
|
Touzeau C, Moreau P and Dumontet C: Monoclonal antibody therapy in multiple myeloma. Leukemia. 31:1039–1047. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lassiter G, Bergeron C, Guedry R, Cucarola J, Kaye AM, Cornett EM, Kaye AD, Varrassi G, Viswanath O and Urits I: Belantamab mafodotin to treat multiple myeloma: A comprehensive review of disease, drug efficacy and side effects. Curr Oncol. 28:640–660. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Anderson LD Jr, Sutherland HJ, Yong K, et al: Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): A dose escalation and expansion phase 1 trial. Lancet Oncol. 19:1641–1653. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, Craigen J, Yates J, Gliddon L, Fieles W, et al: Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 123:3128–3138. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lee HC, Raje NS, Landgren O, Upreti VV, Wang J, Avilion AA, Hu X, Rasmussen E, Ngarmchamnanrith G, Fujii H and Spencer A: Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma. Leukemia. 35:255–258. 2021. View Article : Google Scholar | |
|
Taft D, Henderson C, O'Day C, Yu C, Li H, Ho P and Van Epps H: Pharmacodynamics of SEA-BCMA, a nonfucosylated antibody targeting BCMA, in patients with relapsed/refractory multiple myeloma. Blood. 138(Suppl 1): 11972021. View Article : Google Scholar | |
|
Kumar SK, Migkou M, Bhutani M, Spencer A, Ailawadhi S, Kalff A, Walcott F, Pore N, Gibson D, Wang F, et al: Phase 1, first-in-human study of MEDI2228, a BCMA-targeted ADC in patients with relapsed/refractory multiple myeloma. Blood. 136(Suppl 1): S26–S27. 2020. View Article : Google Scholar | |
|
Xing L, Wang S, Liu J, Yu T, Chen H, Wen K, Li Y, Lin L, Hsieh PA, Cho SF, et al: BCMA-specific ADC MEDI2228 and daratumumab induce synergistic myeloma cytotoxicity via IFN-driven immune responses and enhanced CD38 expression. Clin Cancer Res. 27:5376–5388. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Hoffman JE, Lipe B, Melear J, Liedtke M, Schroeder MA, Niesvizky R, Tomasson MH, Yasenchak CA, Green DJ, Li H, et al: SEA-BCMA, an investigational nonfucosylated monoclonal antibody: Ongoing results of a phase 1 study in patients with relapsed/refractory multiple myeloma (SGNBCMA-001). Blood. 138(Suppl 1): S27402021. View Article : Google Scholar | |
|
Nooka AK, Moreau P, Usmani SZ, Garfall A, van de Donk NWCJ, San-Miguel JF, Rocafiguera AO, Chari A, Karlin L, Mateos MV, et al: Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1. J ClinOncol. 40(16Suppl): S80072022. View Article : Google Scholar | |
|
Huehls AM, Coupet TA and Sentman CL: Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 93:290–296. 2015. View Article : Google Scholar | |
|
Friedrich MJ, Neri P, Kehl N, Michel J, Steiger S, Kilian M, Leblay N, Maity R, Sankowski R, Lee H, et al: The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell. 41:711–725.e6. 2023. View Article : Google Scholar | |
|
Ellerman D: Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. Methods. 154:102–117. 2019. View Article : Google Scholar | |
|
Verkleij CPM, Broekmans MEC, Van Duin M, Frerichs KA, Kuiper R, de Jonge AV, Kaiser M, Morgan G, Axel A, Boominathan R, et al: Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 5:2196–2215. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Atamaniuk J, Gleiss A, Porpaczy E, Kainz B, Grunt TW, Raderer M, Hilgarth B, Drach J, Ludwig H, Gisslinger H, et al: Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Invest. 42:953–960. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Shah Z, Malik MN, Batool SS, Kotapati S, Akhtar A, Rehman OU, Ghani M, Sadiq M, Akbar A, Ashraf A, et al: Bispecific T-cell engager (BiTE) antibody based immunotherapy for treatment of relapsed refractory multiple myeloma (RRMM): A systematic review of preclinical and clinical trials. Blood. 134(Suppl 1): S55672019. View Article : Google Scholar | |
|
Usmani SZ, Garfall AL, Van De Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L, et al: Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study. Lancet. 398:665–674. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Mateos MV, Bahlis NJ, Costa LJ, Perrot A, Pei L, Rubin ML, Lantz K, Sun W, Jaffe M, Kobos R and Nooka AK: MajesTEC-3: Randomized, phase 3 study of teclistamab plus daratumumab versus investigator's choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 40(16 Suppl): TPS80722022. View Article : Google Scholar | |
|
Madduri D, Rosko A, Brayer J, Zonder J, Bensinger WI, Li J, Xu L, Adriaens L, Chokshi D, Zhang W, et al: REGN5458, a BCMA x CD3 bispecific monoclonal antibody, induces deep and durable responses in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 136(Suppl 1): S41–S42. 2020. View Article : Google Scholar | |
|
Lee HC, Bumma N, Richter JR, Dhodapkar MV, Hoffman JE, Suvannasankha A, Zonder JA, Shah MR, Lentzsch S, Maly JJ, et al: LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 41(Suppl 16): S80062023. View Article : Google Scholar | |
|
Rodríguez Otero P, Joseph NS, Kumar SK, Lee HC, Leleu X, Manier S, Dimopoulos MA, Mateos MV, Oriol A, Bumma N, et al: Trial in progress: REGN5458, a BCMAxCD3 bispecific antibody, in a phase Ib multi-cohort study of combination regimens for patients with relapsed/refractory multiple myeloma. Blood. 140(Suppl 1): S4444–S4446. 2022. View Article : Google Scholar | |
|
Solh M, Bahlis N, Raje N, Costello C, Dholaria B, Levy M, Tomasson M, Dube H, Damore M, Lon H, et al: Efficacy and safety of elranatamab (PF-06863135), A B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma. Hematol Transfus Cell Ther. 43(Suppl 1): S195–S196. 2021. View Article : Google Scholar | |
|
Raje NS, Jakubowiak A, Gasparetto C, Cornell RF, Krupka HI, Navarro D, Forgie AJ, Navarro D, Forgie AJ, Udata C, et al: Safety, clinical activity, pharmacokinetics, and pharmacodynamics from a phase I study of PF-06863135, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 134(Suppl 1): S18692019. View Article : Google Scholar | |
|
Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, Tomasson MH, Damore MA, Jiang S, Basu C, et al: Elranatamab in relapsed or refractory multiple myeloma: The MagnetisMM-1 phase 1 trial. Nat Med. 29:2570–2576. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodrίguez-Otero P, Martinez-Lopez J, Koehne G, Touzeau C, et al: Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results. Nat Med. 29:2259–2267. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Weisel K, D'souza A, Hurd D, Voorhees P, Teipel R, Chung A, Rodriguez C, Tuchman S, Korde N, Safah H, et al: P862: A phase 1 first-in-human monotherapy study of ABBV-383, A BCMA x CD3 bispecific T-CELL–redirecting antibody, in relapsed/refractory multiple myeloma. Hemasphere. 7(Suppl): e00363072023. View Article : Google Scholar : | |
|
D'Souza A, Shah N, Rodriguez C, Voorhees PM, Weisel K, Bueno OF, Pothacamury RK, Freise KJ, Yue S, Ross JA, et al: A phase I first-in-human study of ABBV-383, a B-cell maturation antigen x CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 40:3576–3586. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Vij R, Kumar SK, D'Souza A, Mckay JT, Voorhees PM, Chung A, Tuchman SA, Korde N, Weisel K, Teipel R, et al: Updated safety and efficacy results of Abbv-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in a first-in-human phase 1 study in patients with relapsed/refractory multiple myeloma. Blood. 142(Suppl 1): S33782023. View Article : Google Scholar | |
|
Kumar S, D'Souza A, Shah N, Rodriguez C, Voorhees PM, Bueno OF, Buelow B, Freise KJ, Yue S, Pothacamury RK, et al: A phase 1 first-in-human study of Tnb-383B, a BCMA x CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma. Blood. 138(Suppl 1): S9002021. View Article : Google Scholar | |
|
Harrison SJ, Minnema MC, Lee HC, Spencer A, Kapoor P, Madduri D, Larsen J, Ailawadhi S, Kaufman JL, Raab MS, et al: A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE® (bispecific T-cell engager) molecule, in relapsed/refractory (RR) multiple myeloma (MM). Blood. 136(Suppl 1): S28–S29. 2020. View Article : Google Scholar | |
|
Goldstein RL, Goyos A, Li CM, Deegen P, Bogner P, Sternjak A, Thomas O, Klinger M, Wahl J, Friedrich M, et al: AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. Blood Adv. 4:4180–4194. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Costa LJ, Wong SW, Bermúdez A, de la Rubia J, Mateos MV, Ocio EM, Rodríguez-Otero P, San-Miguel L, Li S, Sarmiento R, et al: First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): Interim results of a phase 1 multicenter trial. Blood. 134(Suppl 1): S1432019. View Article : Google Scholar | |
|
Wong SW, Bar N, Victoria Mateos M, Ribas P, Hansson M, Paris L, Hofmeister C, Rodriguez-Otero P, Bermúdez MA, Santoro A, et al: P883: Alnuctamab (ALNUC; BMS-986349; CC-93269), A BCMA x CD3 T-cell engager, in patients (PTS) with relapsed/refractory multiple myeloma (RRMM): Latest results from a phase 1 first-in-human clinical study. Hemasphere. 7(Suppl 1): e12207452023. View Article : Google Scholar | |
|
Wong SW, Bar N, Paris L, Hofmeister CC, Hansson M, Santoro A, Mateos MV, Rodríguez-Otero P, Lund J, Encinas C, et al: Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-cell maturation antigen (BCMA) x CD3 T-cell engager (TCE), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Results from a phase 1 first-in-human clinical study. Blood. 140(Suppl 1): S400–S402. 2022. View Article : Google Scholar | |
|
Roex G, Timmers M, Wouters K, Campillo-Davo D, Flumens D, Schroyens W, Chu Y, Berneman ZN, Lion E, Luo F and Anguille S: Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol. 13:1642020. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Y, Zhang C, Cai D, Zhu R and Cao Y: Exosomal miR-155-5p drives widespread macrophage M1 polarization in hypervirulent Klebsiella pneumoniae-induced acute lung injury via the MSK1/p38-MAPK axis. Cell Mol Biol Lett. 28:922023. View Article : Google Scholar : PubMed/NCBI | |
|
Sperling AS, Derman BA, Nikiforow S, Im SY, Ikegawa S, Prabhala RH, Rodriguez DH, Li Y, Quinn DS, Pearson D, et al: Updated phase I study results of PHE885, a T-charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM). J Clin Oncol. 41(Suppl 16): S80042023. View Article : Google Scholar | |
|
Teoh PJ and Chng WJ: CAR T-cell therapy in multiple myeloma: More room for improvement. Blood Cancer J. 11:842021. View Article : Google Scholar : PubMed/NCBI | |
|
Wehrli M, Gallagher K, Chen YB, Leick MB, McAfee SL, El-Jawahri AR, DeFilipp Z, Horick N, O'Donnell P, Spitzer T, et al: Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). J Immunother Cancer. 10:e0038472022. View Article : Google Scholar : PubMed/NCBI | |
|
Lam N, Trinklein ND, Buelow B, Patterson GH, Ojha N and Kochenderfer JN: Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains. Nat Commun. 11:2832020. View Article : Google Scholar : PubMed/NCBI | |
|
Mehta P, Cron RQ, Hartwell J, Manson JJ and Tattersall RS: Silencing the cytokine storm: The use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol. 2:e358–e367. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Minakata D, Ishida T, Ando K, Suzuki R, Tanaka J, Hagiwara S, Ananthakrishnan R, Kuwayama S, Nishio M, Kanda Y and Suzuki K: Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma. Int J Hematol. 117:729–737. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Wang D, Wang J, Hu G, Wang W, Xiao Y, Cai H, Jiang L, Meng L, Yang Y, Zhou X, et al: A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma. Blood. 137:2890–2901. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Li C, Wang D, Yu Q, Li Z, Wang W, Hu G, Mu W, Li C, An N, Long X, et al: Long-term follow-up of fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma. Blood. 142(Suppl 1): S48542023. View Article : Google Scholar | |
|
Du J, Fu W, Jiang H, Dong B, Gao L, Liu L, Ge J, He A, Li L, Lu J, et al: P869: Updated results of a phase I, open-label study of bcma/cd19 dual-targeting fastcar-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). Hemasphere. 7(Suppl 1): e84060bf2023. View Article : Google Scholar : | |
|
Doucet L, Cailleteau A, Vaugier L, Gourmelon C, Bureau M, Salaud C, Roualdes V, Samarut E, Aumont M, Zenatri M, et al: Prognostic value of hPG80 (circulating progastrin) in IDH-wild type glioblastoma treated with radio-chemotherapy. J Clin Oncol. 40(Suppl 16): S20492022. View Article : Google Scholar | |
|
Mailankody S, Ghosh A, Staehr M, Purdon TJ, Roshal M, Halton E, Diamonte C, Pineda J, Anant P, Bernal Y, et al: Clinical responses and pharmacokinetics of MCARH171, a human-derived bcma targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Final results of a phase I clinical trial. Blood. 132(Suppl 1): S9592018. View Article : Google Scholar | |
|
Yamaguchi Y, Gibson J, Ou K, Lopez LS, Ng RH, Leggett N, Jonsson VD, Zarif JC, Lee PP, Wang X, et al: PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages. J Immunother Cancer. 10:e0044002022. View Article : Google Scholar | |
|
Ledergor G, Fan Z, Wu K, McCarthy E, Hyrenius-Wittsten A, Starzinski A, Chang H, Bridge M, Kwek S, Cheung A, et al: CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 8:3562–3575. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Zwirner NW, Domaica CI and Fuertes MB: Regulatory functions of NK cells during infections and cancer. J Leukoc Biol. 109:185–194. 2021. View Article : Google Scholar | |
|
Padovan E, Terracciano L, Certa U, Jacobs B, Reschner A, Bolli M, Spagnoli GC, Borden EC and Heberer M: Interferon stimulated gene 15 constitutively produced by melanoma cells induces e-cadherin expression on human dendritic cells. Cancer Res. 62:3453–3458. 2002.PubMed/NCBI | |
|
Li W, Zhang B, Cao W, Zhang W, Li T, Liu L, Xu L, Gao F, Wang Y, Wang F, et al: Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing. Exp Hematol Oncol. 12:442023. View Article : Google Scholar : PubMed/NCBI |
